Completed PHASE1 INTERVENTIONAL 1-arm NCT01433068

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity

An Open-Label, Single Arm, Feasibility And Safety Phase I Study With NBTXR3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall

Sponsor: Nanobiotix

Conditions Adult Soft Tissue Sarcoma

Interventions NBTXR3

Updated 6 times since 2017 Last updated: Oct 4, 2020 Started: Oct 31, 2011 Primary completion: May 31, 2014 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Adult Soft Tissue Sarcoma, this trial is completed. The trial is conducted by Nanobiotix and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanobiotix

Data source: Nanobiotix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bordeaux, France
• Villejuif, France